Cellular Biomedicine Group Inc. (CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, has entered into an agreement to acquire from Blackbird Bio Finance University of South Florida’s next generation GVAX vaccine’s (CD40LGVAX) related technologies and know-how for an initial consideration of $2.5 million in cash and $1.75 million in shares of the company’s common stock. CBMG will pay potentially more than $25 million in...